Radium Ra 223 dichloride [clinicaltrials_resource:d54a2106939247fb87d3316c44d0308c]
BAY88-8223, Dose Finding Study in Patients With HRPC [clinicaltrials:NCT00337155]A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate Cancer [clinicaltrials:NCT00459654]BAY88-8223, Does Response Study in HRPC Patients [clinicaltrials:NCT00667199]clinicaltrials:NCT00699751clinicaltrials:NCT01106352Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases [clinicaltrials:NCT01516762]Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients [clinicaltrials:NCT01565746]Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases [clinicaltrials:NCT01618370]Dose Escalation Study of Radium-223 Dichloride in Patients With Advanced Skeletal Metastases [clinicaltrials:NCT01798108]Radium-223 Dichloride (Ra-223 Cl2) Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis [clinicaltrials:NCT01810770]Japanese BAY88-8223 Monotherapy Phase II Study [clinicaltrials:NCT01929655]Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases [clinicaltrials:NCT01934790]clinicaltrials:NCT02023697A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC) [clinicaltrials:NCT02034552]clinicaltrials:NCT02043678clinicaltrials:NCT02097303Radium 223 in Castrate Resistant Prostate Cancer Bone Metastases [clinicaltrials:NCT02135484]clinicaltrials:NCT02141438Radium Ra 223 With Enzalutamide in Men With Metastatic Castration Refractory Prostate Cancer [clinicaltrials:NCT02199197]clinicaltrials:NCT02258451clinicaltrials:NCT02258464clinicaltrials:NCT02312960clinicaltrials:NCT02366130clinicaltrials:NCT02398526NaF/FDG PET/MRI in Measuring Response to Radium Ra 223 Dichloride in Patients With Metastatic Hormone-Resistant Prostate Cancer [clinicaltrials:NCT02429804]Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone Lesions [clinicaltrials:NCT02442063]clinicaltrials:NCT02450812clinicaltrials:NCT02484339Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis [clinicaltrials:NCT02507570]Treatment Patterns in Castrate Resistant Prostate Cancer Patients With Bone Metastases in a Medicare Population [clinicaltrials:NCT02518698]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Radium Ra 223 dichloride [clinicaltrials_resource:d54a2106939247fb87d3316c44d0308c]
Bio2RDF identifier
d54a2106939247fb87d3316c44d0308c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:d54a2106939247fb87d3316c44d0308c
identifier
clinicaltrials_resource:d54a2106939247fb87d3316c44d0308c
title
Radium Ra 223 dichloride
@en
type
label
Radium Ra 223 dichloride [clinicaltrials_resource:d54a2106939247fb87d3316c44d0308c]
@en